Company ProfilePremium

Fuso Chemical Co., Ltd.

Company Profile Analysis

Ticker: 4368.T扶桑化学工業株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Fuso Chemical Co., Ltd. - Company showcase

Year Founded & Workforce

1957

956 Employees

Fuso Chemical Co., Ltd. logo

Fuso Chemical Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Fuso Chemical Co., Ltd. Overview

ItemDetailSource / Note
Legal name扶桑化学工業株式会社 / FUSO CHEMICAL CO., LTD.Annual Securities Report FY2026 cover page
Former namesNone identified for the parent. Subsidiary Qingdao Fuso No.2 Refining & Processing was renamed Fuso Chemical (Qingdao) in Nov 2008.EDINET history section
Founded24 June 1957. It was spun out of the Osaka plant of Teikoku Seiyaku Co., Ltd. with capital of JPY 2 M.Annual Securities Report history; company 2019 retrospective
Incorporation jurisdictionJapan (Osaka)Annual Securities Report
Registered head officeNippon Life Yodoyabashi Bldg. 16F, 3-5-29 Kitahama, Chuo-ku, Osaka 541-0041. Relocated here in Sep 2023.Annual Securities Report FY2026; recruitment disclosures
Second head officeTokyo Head Office, Ogura Bldg. 7F, 6-6 Nihonbashi Kobunacho, Chuo-ku, TokyoCompany recruitment pages
Exchange / tickerTokyo Stock Exchange Prime Market, code 4368. History: JASDAQ OTC in 2001, JASDAQ in 2004, TSE 1st Section from 7 Dec 2015, Prime from 4 Apr 2022.J-LIC listing history; EDINET
ISINThe Japanese ISIN for code 4368 should be confirmed with JPX or a vendor.—
CUSIPNot applicable. No ADR programme was identified.—
Fiscal year end31 MarchAnnual Securities Report
Share capitalJPY 4,334 MCompany recruitment disclosure
Employees (consolidated)956 at FY2026. A non-consolidated trend appears in table 1.3.Annual Securities Report FY2026 via The Shashi
AuditorErnst & Young ShinNihon LLC. FY2026 audit fees were JPY 47 M (JPY 42 M for the parent plus JPY 5 M for network firms).J-LIC; Annual Securities Report via The Shashi
Governance formCompany with an Audit & Supervisory Committee (監査等委員会設置会社), adopted Jun 2018Corporate Governance Report, May 2026
Representative directorsShinichi Sugita (President & CEO); Misako Fujioka (Chairman)Annual Securities Report; AGM notice Jun 2026
Market capitalisationAbout JPY 343.0 bn at ¥3,220 per share (close 30 Sep 2026)Monex Scouter
Shares outstandingAbout 106.5 M post-split. Derived as market cap ÷ price; Traders Web cites roughly 107 M shares issued.Derived
MetricFY2022FY2023FY2024FY2025FY2026
Employees, non-consolidated (persons)491538567588623
Employees, consolidated (persons)————956
Average annual salary, non-consolidated (JPY 10k)678716713725758

Notes on the table:

Source: Annual Securities Reports, compiled by The Shashi.

  • One broker profile shows 930, which probably relates to FY2025.

Segment split of FY2026 headcount: - Electronic Materials: 384

  • Life Science: 516

  • Corporate: 56

Fuso Chemical is an Osaka-based "global niche top" specialty chemical company. It runs two businesses with very different economics.

The first is Electronic Materials. Its core product is ultra-high-purity colloidal silica, sold under the Quartron® brand. This is the nano-abrasive raw material that CMP-slurry makers formulate into slurries used to polish silicon wafers and planarize interconnect layers in advanced logic and memory. Several third-party studies describe Fuso as the world's leading supplier of this product, although their share estimates differ widely. In FY2026 the segment produced 54% of sales but about 75% of segment profit, at a 38.4% operating margin.

The second is Life Science. Fuso is a vertically integrated fruit and organic acid producer with plants in Japan, China, Thailand and the US. Products include malic, citric and gluconic acid, maleic anhydride, fumaric acid, and food-additive preparations. Fuso holds a leading global position in malic acid.

The balance sheet is conservative: a 77% equity ratio and net cash. The investment case now rests on AI-driven semiconductor demand, a JPY 40 bn capacity build at Kyoto due in Feb 2029, and the "Next Growth 2030" plan, which targets JPY 120 bn of sales and JPY 36 bn of operating profit by FY2031.


What the company does: the company's own characterisation (paraphrased)

The Annual Securities Report describes the group as two reportable segments:

Life Science: manufactures and sells fruit acids, organic acids and applied/derivative products for food, beverage, industrial and pharmaceutical uses.

Electronic Materials: manufactures and sells ultra-high-purity colloidal silica and related silica functional materials, mainly for semiconductor polishing.

The corporate motto is 「限りなき進歩と創造」 ("endless progress and creation"). The company states two aspirations:

  • to pursue a "global niche top" position with many "gold-medal" products in specific fields;

  • to contribute to richer lives and a sustainable future.

Independent characterisation

Fuso is effectively two companies sharing one balance sheet.

Electronic Materials: a near-monopoly-like raw-material position. Fuso makes very high-purity colloidal silica by alkoxide-based synthesis (hydrolysis of high-purity silicon alkoxide). This gives exceptional control of:

  • metal impurities;

  • particle-size distribution;

  • coarse-particle counts, a central quality attribute for CMP.

Its patents cover:

  • silica particles with controlled alkoxy-group content;

  • particles with bent or branched structures;

  • particles of 60–130 nm average size with coarse-particle counts held below defined thresholds.

Fuso sells this abrasive raw material to slurry formulators. It does not sell to fabs directly. That places it one tier upstream of the CMP-slurry market and two tiers upstream of the fabs. Its largest disclosed customer is FUJIFILM Electronic Materials Taiwan Co., Ltd., which accounted for:

  • 13.9% of consolidated sales in FY2026;

  • 12.9% (JPY 8,994 M) in FY2025;

  • 15.3% (JPY 9,010 M) in FY2024.

Qualification cycles at slurry makers and fabs are long. That creates high switching costs, but it also slows the conversion of new capacity into sales.

Life Science: a cyclical, more commoditised fruit-acid business with local-for-local production.

Malic acid: made in Osaka (Sakai) and Kashima. Fuso is described as a world-top-class producer.

Citric acid: imported crude citric acid is refined in Qingdao, China, to meet Japanese food-additive specifications. This model dates from the late 1980s, when Chinese crude product often failed Japanese standards.

Gluconic acid and sodium gluconate: produced by PMP Fermentation Products in Peoria, Illinois, USA. Uses include concrete admixtures and metal treatment.

Maleic anhydride and fumaric acid: taken over from Mitsui Chemicals in Oct 2014.

Higher-margin formulations: food-additive preparations such as shelf-life, noodle, deli and tofu preparations; coated organic acids; and high-purity organic acids.

Revenue model

DimensionCharacterisation
Product vs service vs subscription vs licensingEssentially 100% product sales. No material service, subscription or licensing revenue is disclosed.
PricingNegotiated B2B pricing. Electronic Materials pricing is set customer by customer under qualification-based supply agreements. Life Science pricing tracks raw-material costs (corn and sugar feedstocks, petrochemical inputs for maleic/fumaric, Chinese crude citric acid) and FX. Daiwa Securities' initiation (Outperform, 2026) argued that price increases are letting Fuso escape a "supply-responsibility vs profitability" dilemma. That is a broker view, not a company disclosure.
Value-chain positionElectronic Materials: Tier-2 materials supplier (raw abrasive → slurry maker → fab). Life Science: ingredient manufacturer and refiner (feedstock → acid → food/beverage, industrial and pharma customers).
Customer typesElectronic Materials: CMP-slurry formulators (Fujifilm group and others; most names undisclosed). Life Science: food and beverage makers, food-ingredient distributors, concrete-admixture and metal-treatment users, pharma.
End-marketsSemiconductors, especially AI logic and HBM/DRAM requiring advanced CMP steps. Silicon-wafer polishing. Toner, anti-reflective coatings and insulation (new silica applications). Processed food and beverages. Construction (gluconates). Metal processing.
Geographic mix FY2026Japan 44.9%, Asia 38.3%, North America 15.8%, Europe 0.9%, Other 0.1%. Overseas ratio 55.1%.

Strategy

Previous plan: "FUSO VISION 2025" (FY2022–FY2026)

Target (final year FY2026)Original plan (JPY Mn)Revised plan May 2023 (JPY Mn)FY2026 actual (JPY Mn)Status
Net sales58,00085,00076,926Missed by about 9.5%
Operating profit14,00019,00018,850Essentially met
EBITDA20,00030,00029,787Essentially met
Overseas sales ratio (%)—5055.1Exceeded

Announced May 2021; targets raised May 2023.

The plan also included R&D investment of JPY 2 bn; the basis (annual or cumulative) is not clarified in the sources reviewed. Its three management themes were:

  1. capture expanding demand in existing businesses;

  2. invest in and challenge new businesses and fields;

  3. strengthen the management base for sustainable growth, including the SDGs.

New plan: "飛躍2030 / Next Growth 2030" (FY2027–FY2031)

TargetFY2026 actualFY2031 targetImplied 5-yr CAGRSource
Net sales (JPY M)76,926120,0009.3%Tanshin / plan via FilingReader
Operating profit (JPY M)18,85036,00013.8%Same
EBITDA (JPY M)29,78756,700about 13.7% (derived)Same
ROIC (%)11.1≥13—Corporate presentation, Aug 2026
ROE (%)12.9>10, maintained—Same
P/B (x)about 2.5 (Mar 2026)2.5 (KPI)—Same

The document is dated 15 May 2026.

Data conflict. Envalith describes the JPY 36 bn target as ordinary profit. FilingReader's summary and the stated 13.8% CAGR, which reconciles exactly to FY2026 operating profit, indicate it is operating profit.

Strategic themes (paraphrased from the plan, presentations and the Annual Securities Report)

1. Electronic Materials: capacity, qualification, technology.

  • Ramp Kashima Phase 2 through customer qualification.

  • Fill the new Kyoto line. It was qualified earlier than expected and moved to full-scale operation around end-FY2026.

  • Build the JPY 40 bn Kyoto plant (Mar 2026 to Feb 2029). The Mar 2026 disclosure said it would be self-funded. Envalith notes possible use of long-term borrowings.

  • Develop products for finer, multi-layer and higher-performance devices.

2. Diversification of silica. Hollow nano-silica and other new functional materials, explicitly to reduce dependence on semiconductors (Annual Securities Report risk response).

3. Life Science: value-add and overseas.

  • Expand coated organic acids and food-additive preparations.

  • Grow malic-acid share in the US.

  • Expand sodium gluconate at PMP.

4. Capital efficiency.

  • ROIC-based decision framework.

  • Cost of equity estimated at 8–9%.

  • Corporate Value Enhancement Committee.

  • Enhanced investor dialogue under the TSE "cost of capital" initiative; updates were disclosed in May 2024 and May 2025.

5. R&D infrastructure. New R&D centre targeted for 2028; Tokyo Research Lab expanded.

6. Shareholder returns. Six consecutive years of dividend increases; FY2027 DPS forecast of JPY 28 post-split.

Initiatives in the last 24 months

DateInitiativeDetail
Jun 2024Group restructuringFuso Corporation business moved into the parent; entity dissolved 31 Mar 2026
Oct 2024Kyoto new colloidal silica lineCompleted; METI supply-chain subsidy of JPY 3,694 M approved Jun 2026
May 2025Cost-of-capital disclosure updateROE ≥10% commitment; cost-of-equity reassessment; IR enhancement
Aug–Dec 2025Kashima Phase 2JPY 20.7 bn; completed Aug 2025; full operation Dec 2025
Mar 2026Kyoto JPY 40 bn plantApproved 13 Mar 2026; start-up Feb 2029; JPY 403 M spent by end-FY2026
Apr 20263:1 stock splitTo improve liquidity and broaden the investor base
May 2026Next Growth 2030See 10.2
2,026PMP sodium gluconate expansion—
Aug 2026Corporate Value Enhancement Committee; ROIC ≥13% targetCorporate presentation

No quantified emissions-reduction target was verified in the sources reviewed.

Cost programmes: no formal cost-reduction programme with quantified targets has been disclosed.

Management guidance, FY2027

MetricFY2026 actualFY2027 guidance (latest)YoY
Net sales (JPY M)76,92685,800+11.5%
Operating profit (JPY M)18,85024,300+28.9%
Ordinary profit (JPY M)19,57324,500+25.2%
Net income (JPY M)14,31119,200+34.2%
EBITDA (JPY M)29,787about 37000+24.2%
EPS (JPY)135.28181.48—
DPS (JPY)27.3328.00—
H1 ordinary profit (JPY M)9,80711,700—
H1 net income (JPY M)6,87910,450—

Notes on guidance:

  • Net income guidance was raised on 17 Jun 2026 from JPY 16,600 M to JPY 19,200 M because of the subsidy. EPS guidance was raised from JPY 156.90 to JPY 181.48.

  • Guidance excludes potential impacts of Middle East instability, per the May 2026 Tanshin.

Products & Services

Pricing models are not publicly disclosed for any product. All are negotiated B2B sales.

Electronic Materials Business

Product / brandDescription & key capabilitiesTarget customerLaunch / latest
Quartron® ultra-high-purity colloidal silica (CMP grade)Nano-scale silica particles in water, made by alkoxide synthesis. Very low metal impurities, tight particle-size-distribution control and reduced coarse particles. Used as the abrasive in CMP slurries for oxide, interconnect and other planarization steps. Third-party reports cite purity of up to 99.9999%, which is not company-verified. Envalith reports adoption in processes at the 1.8 nm node and beyond, citing company disclosures.CMP-slurry formulators, e.g. FUJIFILM Electronic Materials TaiwanTrial production 1987; capacity added at Kyoto 2005, 2007 and 2024, Kashima 2023 and 2025, and Kyoto new plant (2029)
Quartron® for silicon-wafer polishingColloidal silica grades for polishing prime silicon wafers (stock and final polish)Wafer-polishing slurry makers and wafer producersLong-established
Engineered-morphology colloidal silicaParticles with bent or branched (non-spherical) structures, high aggregation ratio, controlled density and alkoxy-group content. Designed for faster removal rates and lower defectivity.Advanced-node slurry formulatorsCovered by recent patent filings (IPqwery listing)
Hollow nano-silicaHollow silica nanoparticles for anti-reflection and thermal insulation, aimed at diversifying away from semiconductorsOptical film and coating makers, insulation materialsUnder development and early commercialisation (Annual Securities Report risk section)
Hydrophobic silica powder for tonerSurface-treated nano-silica powders as external additives for toner resin particlesToner manufacturersPatented; in commercial use (company recruitment disclosure)
Silica for resin additives and other functional usesNano-silica fillers for resins and coatingsResin compoundersCommercial
Resin additives (isobutylene derivatives)Historical "functional chemicals" productsResin and polymer makersSince 1966; formerly in the old segment name

Life Science Business

Product / brandDescriptionTarget customerLaunch / latest
Malic acid (food, FDA and industrial grades)Acidulant for beverages, confectionery and processed foods; also industrial and pharma uses. Produced in Osaka (Sakai) and Kashima.Food and beverage makers worldwide1962; FDA grade 1975; Kashima plant 2019
Citric acid and sodium citrateCrude citric acid refined in Qingdao to Japanese food-additive standards; also high-purity industrial gradesFood, beverage and industrial cleaning customers1986/1987; Qingdao refining since 1994
Gluconic acid, sodium gluconate (PMP Fermentation Products, USA)Fermentation-based products for concrete admixtures, metal surface treatment, cleaning and food. An expansion investment for sodium gluconate at PMP has been decided.Construction chemicals and industrial customers in North AmericaAcquired 2003; expansion under way
Maleic anhydride, fumaric acidPetrochemical-route organic acids for resins (unsaturated polyester), food acidulants (fumaric) and other usesResin makers, foodAcquired from Mitsui Chemicals Oct 2014
Other fruit/organic acidsLactic, tartaric, succinic, ascorbic, acetic and maleic acid (some traded)Food industryOngoing
Food-additive preparations (FFA)Blended functional preparations: antioxidant preparations, noodle-skin preparations, deli preparations, tofu preparations, shelf-life improversJapanese food processorsOngoing; management priority for growth
"Aplucol" (アプルコール)Alcohol-based food preservative preparationFood processors1,981
"W-Clean" (Wクリーン)Algae-removal agent for nori (seaweed) aquacultureNori farmers1,982
Coated organic acidsEncapsulated acids for controlled release in food processingBakery and confectionery makersExpansion targeted under the current plan
High-purity organic acidsHigh-purity grades for electronics and pharmaElectronics and pharma customersOngoing
Stress-free preparations (ストレスフリー製剤)Functional formulations; details not disclosedFood and healthListed in the company product overview

Financial Detail

Segment Overview

SegmentContentsKey products

Life Science Business (ライフサイエンス事業)

Fruit and organic acids for food, industrial and pharmaceutical uses; high-value-added applied products

Malic acid, citric acid and sodium citrate, gluconic acid and sodium gluconate (PMP, US), lactic/tartaric/succinic/ascorbic/acetic acids (some traded), maleic anhydride, fumaric acid, food-additive preparations (FFA), coated organic acids, high-purity organic acids, "stress-free" preparations

Electronic Materials Business (電子材料事業)

Ultra-high-purity colloidal silica and silica functional materials

Quartron® ultra-high-purity colloidal silica (CMP abrasive raw material), hollow nano-silica, hydrophobic silica powders for toner, other silica functional materials

Revenue by Segment

Segment (JPY Mn)FY2024FY2025FY2026

Life Science revenue

34,14336,28835,411

Electronic Materials revenue (new definition)

—33,21441,515

Electronic Materials & Functional Chemicals revenue (former definition)

24,827——

Consolidated revenue

58,97069,50176,926

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

Segment (JPY Mn)FY2024FY2025FY2026

Life Science segment profit

5,6375,2895,308

Electronic Materials segment profit (new definition)

—13,17115,927

Electronic Materials & Functional Chemicals segment profit (former definition)

7,533——

Corporate / eliminations

-2,087-2,230-2,384

Consolidated operating profit

11,08316,23018,850

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2024FY2025FY2026

Life Science operating margin

16.514.615.0

Electronic Materials operating margin

30.339.738.4

Life Science revenue YoY growth

-9.76.3-2.4

Electronic Materials revenue YoY growth

-19.033.825.0

Life Science share of consolidated revenue

57.952.246.0

Electronic Materials share of consolidated revenue

42.147.854.0

Electronic Materials share of total segment profit

57.271.375.0

Segment Assets & Liabilities

Metric (JPY Mn)FY2024FY2025FY2026

Electronic Materials segment assets

63,18672,60872,708

Life Science segment assets

38,71338,54840,402

Electronic Materials capex (incl. intangibles)

11,57514,5677,926

Life Science capex (incl. intangibles)

2,4331,3712,734

Electronic Materials depreciation

5,3376,5229,095

Life Science depreciation

1,6161,5701,638

Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (JPY Mn)

55,76068,45958,97069,50176,926

Cost of sales (JPY Mn)

32,67940,04838,39743,53147,609

Gross profit (JPY Mn)

23,08128,41120,57325,97129,317

SG&A (JPY Mn)

8,0469,4809,4899,74010,466

Operating profit (JPY Mn)

15,03418,93011,08316,23018,850

Depreciation & amortisation (JPY Mn)

4,4534,3387,1608,30910,937

EBITDA (JPY Mn)

19,48823,26818,24424,53929,787

Ordinary profit (JPY Mn)

15,50919,74011,88316,56119,573

Pre-tax income (JPY Mn)

15,71320,08212,00616,26719,528

Income taxes (JPY Mn)

4,8235,9523,6624,6445,216

Net income attributable to owners (JPY Mn)

10,89014,1298,34311,62214,311

Comprehensive income (JPY Mn)

12,07014,3289,83611,39915,932

Per-Share Data and Key Financials (JPY)

MetricFY2022FY2023FY2024FY2025FY2026

EPS basic, post-split (JPY)

102.69133.6378.90109.89135.28

EPS diluted, post-split (JPY)

102.69133.6378.90109.89135.28

DPS, post-split (JPY)

18.3321.0022.0024.3327.33

DPS, pre-split as declared (JPY)

5563667382

BPS, post-split (JPY)

712.21827.60898.59983.721,107.94

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

41.441.534.937.438.1

Operating margin

27.027.718.823.424.5

EBITDA margin

34.934.030.935.338.7

Net margin

19.520.614.116.718.6

Revenue growth YoY

32.122.8-13.917.910.7

Effective tax rate

30.729.630.528.526.7

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (JPY Mn)

92,010113,529133,740141,502152,256

Cash & deposits (JPY Mn)

24,23623,41231,47131,29541,006

Short-term borrowings incl. current portion of LTD (JPY Mn)

0003,1004,000

Long-term debt (JPY Mn)

0020,00016,90012,900

Total debt (JPY Mn)

0020,00020,00016,900

Net debt (JPY Mn; negative = net cash)

-24,236-23,412-11,471-11,295-24,106

Net assets / equity (JPY Mn)

75,30387,50395,025104,049117,217

Intangible assets incl. goodwill (JPY Mn)

1,9041,3463,1294,0065,490

Inventories (JPY Mn)

11,97816,04017,41618,15318,409

Trade receivables (JPY Mn)

14,87214,95416,44516,03216,610

Total current assets (JPY Mn)

52,07855,34468,13367,05278,476

Total current liabilities (JPY Mn)

———18,49019,844

Working capital (JPY Mn)

———48,56258,632

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (JPY Mn)

10,19913,9267,06122,70224,794

Capital expenditure, cash (JPY Mn)

9,22613,43314,94418,3547,349

Free cash flow (JPY Mn)

973493-7,8834,34817,445

Investing cash flow (JPY Mn)

-9,375-13,418-18,576-20,538-11,069

Dividends paid (JPY Mn)

1,7692,1142,3252,3962,785

Share buybacks (JPY Mn)

1,1080110

Debt issued (JPY Mn)

0020,00000

Debt repaid (JPY Mn)

00003,100

Financing cash flow (JPY Mn)

-2,882-2,12517,664-2,409-5,905

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

15.417.49.111.712.9

ROA, net income / total assets (%)

11.812.46.28.29.4

ROIC, company definition (%)

————11.1

Current ratio (x)

———3.633.95

Debt / equity (x)

0.000.000.210.190.14

Net debt / EBITDA (x)

-1.24-1.01-0.63-0.46-0.81

Interest coverage, OP / interest expense (x)

——91.6123.9153.3

Asset turnover (x)

0.610.600.440.490.51

Days sales outstanding (days)

97.479.7101.884.278.8

Days inventory outstanding (days)

133.8146.2165.6152.2141.1

Days payables outstanding (days)

34.030.022.425.821.7

Cash conversion cycle (days)

197.2195.9245.0210.6198.2

Revenue by Region and Revenue by Region (%)

Region (JPY Mn)FY2022FY2023FY2024FY2025FY2026

Japan

29,55134,05631,27234,31134,531

Asia

14,96721,32617,03823,54429,500

North America

10,11511,4359,99210,80912,127

Europe

9391,404547730675

Other

18823912110794

Overseas sales ratio (%)

47.050.347.050.655.1

Region growth YoY (%)

Region growth YoY (%)FY2024FY2025FY2026

Japan

-8.29.70.6

Asia

-20.138.225.3

North America

-12.68.212.2

Europe

-61.033.5-7.5

Other

-49.4-11.6-12.1

Share Price History

DatePrice (JPY)NoteSource

6 Jan 2026

2,107

Year-to-date low per Yahoo! Finance. Traders Web shows a ¥2,632 low on 31 Mar 2026; the two sources use different split adjustments.

Yahoo! Finance JP; Traders Web

3 Feb 2026

2,517

Split-adjusted close

Kabutore

31 Mar 2026

2,726

FY-end price (company)

Corporate presentation, Aug 2026

22 Jun 2026

4,995

Year-to-date high

Yahoo! Finance JP

10 Jul 2026

4,040—

Yahoo! Finance JP

10 Aug 2026

3,355

-11.9% post-Q1

Traders Web

17 Sep 2026

2,913—

Kabuyoho

30 Sep 2026

3,220

Latest verified close

Monex Scouter

Valuation Multiples

MultipleFuso ChemicalNissan Chemical (reference)

P/E, trailing (FY2026 EPS 135.28)

23.8x

16.3x (EDINET DB snapshot)

P/E, forward (FY2027 company EPS 181.48)

17.7x (Monex)

—

P/E, forward excluding subsidy (EPS about 156.9)

20.5x—

EV/EBITDA, FY2026 (EV about JPY 318.9 bn)

10.7x—

EV/EBITDA, FY2027E (EBITDA about JPY 37.0 bn)

8.6x—

EV/Sales, FY2026

4.1x—

P/B (actual)

2.77x (Monex)

3.15x (EDINET DB snapshot)

Dividend yield (FY2027E JPY 28)

0.87%

3.37% (EDINET DB snapshot)

Capital Markets

ItemValueSource

Rating (average)

4.75 / 5 (bullish)

Kabuyoho (Sep 2026)

Average target price

JPY 6,350. Treat with caution; it may include stale or unadjusted targets.

Kabuyoho

FY2027 consensus sales

JPY 90,420 M

Kabuyoho (Aug 2026)

FY2027 consensus operating profit

JPY 25,770 M

Kabuyoho

FY2027 consensus ordinary profit

JPY 26,053–26,495 M (varies by date)

Kabuyoho

FY2027 consensus net income

JPY 20,438 M

Kabuyoho

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026FY2027

DPS, post-split (JPY)

18.3321.0022.0024.3327.3328.00

Payout ratio (%)

17.915.727.922.120.215.4

Capital Markets — Credit ratings

ItemDetail

Credit ratings (Moody's / S&P / Fitch)

None identified; the company does not appear to be publicly rated. No R&I or JCR rating was identified either.

Debt instruments

Bank term loan of JPY 20,000 M drawn in FY2024; no bonds

Outstanding at 31 Mar 2026

JPY 16,900 M (JPY 4,000 M due within one year; JPY 12,900 M long-term)

Repayment history

JPY 3,100 M repaid in FY2026

Maturity profile beyond FY2027

On a straight-line basis (analyst assumption), the remaining JPY 12.9 bn amortises over about 3–4 years.

Interest expense

JPY 123 M in FY2026 (about 0.7% implied rate)

Analyst Conclusions

Guidance versus consensus

MetricFY2026 actualFY2027 company guidanceFY2027 consensusFY2031 plan
Net sales (JPY M)76,92685,80090,420120,000
Operating profit (JPY M)18,85024,30025,77036,000
Net income (JPY M)14,31119,20020,438—

Consensus sits about 5–6% above company guidance. That is consistent with management's history of conservative initial guidance (FY2025: initial OP guidance JPY 11.15 bn, actual JPY 16.23 bn).

Bull case

  1. Volume ramp is already visible.

    • Q1 FY2027 sales rose 22.3% and OP 31.5%. Q1 delivered 26.0% of full-year ordinary-profit guidance.

    • Kashima Phase 2 entered full operation only in Dec 2025, and its qualification-driven volume is still ramping.

    • That makes the FY2027 OP guide of JPY 24.3 bn look achievable, with upside toward consensus of JPY 25.8 bn.

  2. Structural CMP-intensity growth plus near-monopoly economics.

    • Electronic Materials generated about 60% segment EBITDA margins in FY2026.

    • With the dominant share of a niche that adds CMP steps at every node and in HBM, incremental capacity (Kyoto 2029) should earn returns well above the 8–9% cost of equity. That supports the ROIC ≥13% target.

  3. Valuation reset and balance-sheet optionality.

    • After the 36% drawdown from June, the stock trades at about 17.7x company-guided FY2027 EPS and about 8.6x FY2027E EV/EBITDA, with net cash.

    • A modest payout increase or buyback would address the low 0.87% yield and the PBR-2.5x KPI.

Bear case

  1. Cyclical peak risk.

    • FY2024 showed how fast earnings can fall: OP -41% on a memory downturn plus inventory correction.

    • The market sold the stock 12% on the H1 guide, which implies Q2 ordinary profit of about JPY 5.3 bn against JPY 6.4 bn in Q1, a sequential slowdown.

    • If AI capex digestion arrives in 2027, new capacity will be under-utilised just as depreciation rises.

  2. Capex-heavy plan with a credibility gap.

    • The previous plan missed its sales target by about 9.5%.

    • The new plan needs +56% sales and +91% OP in five years.

    • The JPY 40 bn Kyoto project (about 34% of equity) does not contribute until FY2029–FY2030 and will add about JPY 3–4 bn a year of depreciation (analyst estimate). FCF will compress again in FY2027–FY2029.

  3. Concentration and localisation risk, plus a stagnant second leg.

    • One customer accounts for 13.9% of sales.

    • Chinese high-purity silica suppliers are emerging under state support.

    • Life Science profit has been flat at about JPY 5.3 bn for three years and faces Chinese overcapacity.

    • The "two-pillar" story therefore leans entirely on semiconductors.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
Late Oct 2026H1 FY2027 resultsQ2 ordinary profit against the implied about JPY 5.3 bn; any full-year guidance raise; Electronic Materials margin
OngoingKashima Phase 2 qualification progressCustomer approvals and utilisation commentary
OngoingKyoto JPY 40 bn constructionCost and schedule versus the Feb 2029 start-up; any shift to borrowing
Feb 2027Q3 FY2027 resultsRun-rate toward the JPY 24.3 bn OP guide
May 2027FY2027 results and FY2028 guidanceFirst-year progress on Next Growth 2030; dividend policy
2026–2027Capital policyBuybacks or payout increase to meet PBR and ROIC KPIs
MacroAI and HBM capex; memory pricing; JPY/USDLeading indicators for silica demand and translation
CompetitiveChinese colloidal-silica qualification winsShare-erosion risk
Life ScienceChina and Europe demand; PMP expansionReturn to segment-profit growth

Analyst verdict

Business quality. Fuso Chemical is a high-quality, under-followed global niche leader. It is going through its most consequential capital cycle since founding.

  • Its Electronic Materials franchise is the world's leading supplier of ultra-high-purity colloidal silica for CMP. On disclosed segment data it earns about 38% operating and about 60% EBITDA margins.

  • Those economics are protected by purity know-how, long qualification histories and policy recognition, as the June 2026 METI subsidy shows.

  • The balance sheet carries net cash and a 77% equity ratio, so the JPY 40 bn Kyoto expansion is financially comfortable.

What the investment case depends on. The case is no longer about whether Fuso has a moat; it does. It is about three things:

Timing: filling Kashima Phase 2 before the next semiconductor down-cycle.

Discipline: delivering Kyoto on budget by Feb 2029 and lifting ROIC from 11.1% to at least 13%.

Capital allocation: the current roughly 20% payout and absent buybacks sit awkwardly with a stated PBR-2.5x KPI.

Execution record. FY2024 is the stress test to remember: revenue fell 14% and OP 41% in a single year. The previous medium-term plan's sales miss tempers confidence in the JPY 120 bn FY2031 target. Against that, management guides conservatively; FY2025 OP beat the initial guide by 46%. Q1 FY2027 was strong and above consensus.

Valuation. After the post-Q1 sell-off, the shares trade at about 17.7x guided FY2027 EPS, about 20.5x excluding the one-off subsidy, and about 8.6x FY2027E EV/EBITDA. That is reasonable for a business compounding segment EBITDA in the high teens, albeit with cyclical beta.

Overall view: constructive, with a cyclical risk overlay. The stock is best owned by investors with conviction in multi-year CMP intensity growth from AI and HBM, who can tolerate drawdowns of 30–40% such as the one seen in 2026.

Key upside triggers:

  • evidence of price increases sticking;

  • faster Kashima qualification;

  • a shift in shareholder returns.

Key downside triggers:

  • a sequential Electronic Materials slowdown in H1 results;

  • any slippage or overrun at Kyoto;

  • a qualified Chinese competitor at a major slurry customer.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleBackground / prior rolesAGM approval % (Jun 2026)Independent

Shinichi Sugita (杉田 真一)

Representative Director, President & CEO (since 2020)

Joined Fujisawa Pharmaceutical (now Astellas) in Apr 1980; joined Fuso through the 2003 acquisition of Fujisawa's chemicals business

95.78

No

Misako Fujioka (藤岡 実佐子)

Representative Director, Chairman

Outside director of Fuso from Jun 1988; long-serving board member; individual shareholder (3.0–3.25% in historical filings)

96.50

No

Haruo Masauji* (政氏 晴生)

Senior Managing Director, GM Life Science Business Unit

Joined Fuso Apr 1990; previously GM Electronic Materials Business Unit and in charge of innovation

98.49

No

Motoki Sugimoto (椙本 源樹)

Director, GM Electronic Materials Business Unit

Joined Fuso Apr 1992; previously GM Life Science

98.49

No

Atsushi Fujioka* (藤岡 篤)

Managing Director, GM Corporate Planning

Joined Fuso Nov 2019

98.59

No

Hiroyuki Ito (伊藤 裕之)

Director, GM Administration Headquarters

Former Senior Executive Officer, Administration

98.48

No

Norikazu Miyamoto* (宮本 典和)

Director, GM Production Headquarters

—98.48

No

Sayaka Eguro* (江黒 早耶香)

Director, Audit & Supervisory Committee Member

Attorney; registered with Daiichi Tokyo Bar Association in 2008; Soga, Uryu & Itoga

99.43

Yes

百嶋 計

Outside Director

Joined Ministry of Finance in 1981

99.30

Yes

Takashi Takeuchi* (武内 敬)

Director, Audit & Supervisory Committee Member

Joined Osaka Gas in 1987

99.35

Yes

Toshihide Tominaga* (富永 俊秀)

Director (newly elected Jun 2026)

—99.50—

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

1957–2018

Founder Shozo Akazawa leads

Founder era. The Shashi also records Ryota Akazawa as president around FY2019; sources conflict on the exact 2018–2019 sequence.

2018

Yoshinobu Nakano (ex-Inabata & Co.) becomes President

First non-family professional CEO

2020

Shinichi Sugita becomes President & CEO

Presided over the Kashima/Kyoto capacity build and the AI-cycle earnings records

2018 onward (various)

Departed directors: Takashi Tanimura (Senior Managing Director, international), Tomomi Tada (ex-Teikoku Seiyaku), and several Audit & Supervisory Committee members

Routine rotation

Jun 2026

Toshihide Tominaga elected

Board strengthening alongside the new plan

Directors' Remuneration

Metric (JPY Mn)FY2022FY2023FY2024FY2025FY2026

Total director remuneration (JPY Mn)

303312285364389

Fixed remuneration (JPY Mn)

169171177208192

Bonus (JPY Mn)

13414186126164

Stock-based (JPY Mn)

00213033

Number of directors covered

66668

Major Shareholders

RankShareholderTypeStake (%)
1

壽世堂 (Jusei-do), Akazawa-family-linked asset company (inferred, not confirmed)

Strategic / founding family

15.87
2

Teikoku Seiyaku Co., Ltd. (origin parent)

Strategic

9.44
3

The Master Trust Bank of Japan (trust a/c)

Custodian / institutional

9.19
4

薫風舎 (Kunpu-sha), private holding company (inferred, not confirmed)

Strategic / family

7.43
5

Custody Bank of Japan (trust a/c)

Custodian / institutional

6.52
6

Osaka Small and Medium Business Investment & Consultation Co.

Financial

4.23
7

有限会社帝産 (Teisan)

Strategic (Teikoku-linked, inferred)

3.90
8

The Bank of New York Mellon 140042

Foreign custodian

2.86
9

Akazawa Memorial Foundation (公益財団法人赤澤記念財団)

Foundation (founder-linked)

2.84
10

US Bank National Association JP Accts TS

Foreign custodian

2.01

Competitive Landscape

Competitors by Segment

SegmentCompetitorHQRelevant productsRelative positioning

Electronic Materials

Nissan Chemical Corp. (TSE 4021)

Japan

"Snowtex" colloidal silica; semiconductor materials (ARC, resist underlayers)

Broad-based; strong in colloidal silica, but Fuso is seen as the leader in ultra-high-purity alkoxide CMP grade

Electronic Materials

Merck KGaA (EMD Electronics, incl. ex-Versum)

Germany

Colloidal silica and CMP slurries

Integrated slurry and abrasive capability

Electronic Materials

Evonik Industries

Germany

Fumed and colloidal silica; CMP-grade colloidal silica capacity

Expanding CMP-grade supply

Electronic Materials

Nouryon (Levasil)

Netherlands/Sweden

Colloidal silica (mostly industrial; some electronics)

Volume leader in industrial grades

Electronic Materials

W. R. Grace (LUDOX)

USA

Colloidal silica

Industrial and specialty; building high-purity offer

Electronic Materials

Ecolab / Nalco

USA

Colloidal silica

Industrial

Electronic Materials

Shanghai Xin'anna Electronic Technology; Suzhou Nanodispersions

China

High-purity colloidal silica

Emerging domestic Chinese suppliers, a localisation threat

Electronic Materials (adjacent)

Fujimi Inc.; Entegris (CMC Materials); Resonac; Fujifilm

Japan/USA

CMP slurries

Customers who could vertically integrate into abrasive synthesis

Life Science

Bartek Ingredients

Canada

Malic and fumaric acid

Major North American malic producer

Life Science

Polynt

Italy

Malic acid, maleic anhydride

European competitor

Life Science

Thirumalai Chemicals

India

Malic acid, maleic anhydride

Low-cost Asian competitor

Life Science

Changmao Biochemical and other Chinese producers

China

Malic and other acids

Price-setting Chinese capacity

Life Science

Jungbunzlauer

Switzerland

Citric acid, gluconates

Global citric and gluconate leader

Life Science

Weifang Ensign, COFCO Biochemical, Shandong producers

China

Citric acid

Dominant global citric-acid supply

Life Science

Roquette; ADM; Cargill

France/USA

Gluconates and fermentation acids

Gluconate competitors to PMP

Competitor Detail

SourceEstimate

ReportPrime (Apr 2026)

Fuso reportedly supplies about 90% of CMP-grade colloidal-silica raw abrasive. Market size estimated at US$258.6 M in 2025.

ReportPrime company-ranking page

Nissan Chemical, Fuso and Cabot together hold about 45%; market US$240 M in 2024; 7.73% CAGR

Industry blog citing a market report

Fuso, Merck and Evonik together hold about 68% of high-purity colloidal silica

DCF-analysis SWOT (Apr 2026)

Fuso holds more than 50% of ultra-high-purity colloidal silica (late 2025)

Peer Comparison FY2027

MetricFuso ChemicalNissan Chemical

Revenue (JPY Mn or as stated)

76,926279,586

Revenue growth YoY (%)

10.711.2

Operating margin (%)

24.522.7

ROE (%)

12.920.3

Equity ratio (%)

77.071.9

Recent Developments

*Note on the 10 Aug 2026 reaction. The company gave no specific explanation.

H1 ordinary-profit guidance of JPY 11.7 bn implies Q2 of only about JPY 5.3 bn after a JPY 6.4 bn Q1.

Both the H1 and full-year guides sit 6–8% below consensus.

The market read this as a sequential slowdown and possibly management conservatism.

Company Snapshot

$513.9M

Revenue

956

Employees

1957

Founded

SWOT Analysis

Strengths

  • Profit engine. Electronic Materials posted a 38.4% operating margin and about 60% segment EBITDA margin in FY2026, versus a chemical-industry median OP margin of about 7% (EDINET DB, 158 companies).
  • Balance sheet. Equity ratio of 77.0%, net cash of JPY 24.1 bn, Altman Z-score of 7.29, and Piotroski F-score of 8/9 (EDINET DB, FY2026).
  • Cash generation. Record operating cash flow of JPY 24.8 bn and FCF of JPY 17.4 bn in FY2026, with FCF/NI conversion of about 98–122% depending on the capex definition.
  • Capacity lead. Kashima Phase 1 (2023) and Phase 2 (2025, JPY 20.7 bn) and the Kyoto new line (2024) are online, and JPY 40 bn of Kyoto capacity is due in Feb 2029. Competitors would need years and qualification to match.
  • Qualification moat. Reported adoption in 1.8 nm-class processes. The Kyoto line qualified earlier than expected (company commentary, FY2026).
  • Policy support. A JPY 3,694 M METI supply-chain subsidy (Jun 2026) marks Fuso as strategically important to Japan's semiconductor supply chain.
  • Stable governance and ownership. About 40%+ held by long-term founding and strategic holders. Six consecutive dividend increases.

Weaknesses

  • Customer concentration. FUJIFILM Electronic Materials Taiwan accounted for 13.9% of FY2026 sales (15.3% in FY2024).
  • Working capital. A cash conversion cycle of about 198 days and inventory days of about 141 in FY2026 weigh on ROIC (11.1%, company definition).
  • Life Science stagnation. Sales fell 2.4% in FY2026, and segment profit has stayed at JPY 5.3–5.6 bn for three years, below the JPY 7.4 bn peak in FY2023.
  • Plan credibility. FUSO VISION 2025 missed its revised sales target by about 9.5% (JPY 76.9 bn against JPY 85 bn).
  • Limited disclosure. No segment-by-geography matrix, no quarterly segment detail in some releases, no R&D or patent quantification in summary materials, and no ESG ratings disclosed.
  • Low gender diversity. Women hold 1.7% of management positions (EDINET DB).
  • Low payout. About 20% of EPS. The DPS forecast of JPY 28 for FY2027 implies a 15% payout on guided EPS. The dividend yield of about 0.87% is unattractive to income investors.

Opportunities

  • AI-driven CMP intensity. HBM, advanced packaging and gate-all-around logic raise CMP step counts. FY2026 Asia sales rose 25.3%.
  • Kashima Phase 2 qualification is converting to volume from FY2027. Q1 FY2027 sales rose 22.3%.
  • Price increases. Daiwa's initiation thesis is that price increases can lift returns on new capacity.
  • Silica diversification. Hollow silica, toner powders and new functional materials.
  • Life Science value-add. Coated acids, preparations, US malic-acid share gains, and the PMP gluconate expansion.
  • Capital efficiency. With net cash of JPY 24 bn and P/B around 2.8x, buybacks or a higher payout could lift ROE. The ROIC ≥13% KPI is now explicit.

Threats

  • Semiconductor cyclicality. The FY2024 precedent saw revenue fall 13.9% and OP fall 41% in one year.
  • Chinese localisation. Domestic Chinese high-purity colloidal silica suppliers are emerging with policy backing.
  • Technology substitution. The Annual Securities Report itself flags that innovation in semiconductors could change the market, for example through new planarization approaches or ceria abrasives.
  • Raw-material and geopolitical exposure. Heavy procurement from China; Middle East conflict cost inflation (Feb 2026 onward); excluded from guidance.
  • FX. Yen appreciation would hit translation and export margins; Q1 FY2026 comprehensive income fell 27.7% on FX.
  • Execution risk. The JPY 40 bn Kyoto project equals about 34% of equity and about 2x FY2026 operating cash flow. Overruns occurred at Kashima Phase 2 (+3.6%).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 2025FY2025 results: sales JPY 69,501 M (+17.9%), OP JPY 16,230 M (+46.4%), NI JPY 11,622 M (+39.3%). DPS JPY 73 (pre-split). FY2026 DPS guidance JPY 76.Record year; recovery from the FY2024 trough confirmed
12 May 2025Update on cost-of-capital-conscious management: commitment to ROE ≥10%, reassessment of cost of equity, more IRResponse to TSE capital-efficiency push
19–20 Jun 2025FY2025 Annual Securities Report filed; AGM heldRoutine
8 Aug 2025Q1 FY2026: sales JPY 18,658 M (+7.0%), OP JPY 4,694 M (+20.0%). Comprehensive income -27.7% on FX.Margin expansion despite yen-driven OCI drag
Aug 2025Kashima Phase 2 colloidal silica facility completed (total JPY 20,723 M against a JPY 20,000 M budget)Major capacity addition; qualification phase begins
31 Oct 2025H1 FY2026: sales JPY 37,705 M, OP JPY 9,746 M. H1 and full-year forecasts revised up; interim and year-end dividend forecasts raised.Positive earnings momentum
Dec 2025Kashima Phase 2 begins full-scale operationVolume contribution from FY2027
Late FY2026New Kyoto line clears qualification earlier than expected and moves to full-scale operation (per company commentary relayed by Envalith)Faster ramp than planned
6 Feb 2026Q3 FY2026: 9M sales JPY 57,928 M (+10.5%), OP JPY 14,563 M (+15.6%)Record 9M
Feb 2026Military conflict in the Middle East raises raw-material and fuel costs (industry-wide; noted in peer disclosures). Fuso's FY2027 guidance excludes these impacts.Macro risk flag
13 Mar 2026Board decides on a JPY 40 bn ultra-high-purity colloidal silica facility at the Kyoto Site; start-up Feb 2029Largest investment in company history; underpins the 2030 plan
Mar 2026Kyoto construction begins (JPY 403 M spent by 31 Mar 2026)Execution under way
27–30 Mar 2026Last cum-split trading day and ex-date for the 3:1 splitLiquidity measure
31 Mar 2026Fuso Corporation dissolved; share price JPY 2,726 (post-split basis)Group simplification
1 Apr 20263-for-1 stock split takes effectLower minimum investment
11 May 2026FY2026 results: record sales JPY 76,926 M, OP JPY 18,850 M, NI JPY 14,311 M. DPS JPY 82 (pre-split). FY2027 guidance: sales JPY 85.8 bn, OP JPY 24.3 bn.Record year; strong guide
11–15 May 2026"Next Growth 2030 / 飛躍2030" plan: FY2031 sales JPY 120 bn, OP JPY 36 bn, EBITDA JPY 56.7 bnNew multi-year roadmap
14 May 2026Corporate Governance Report: 12 directors, 5 independentGovernance enhancement
22 May 2026Results briefing for institutional investorsIR
17 Jun 2026METI supply-chain subsidy of JPY 3,694 M approved for Kyoto equipment. NI guidance raised to JPY 19,200 M; H1 NI guidance to JPY 10,450 M.Non-operating EPS uplift; signals policy support
19 Jun 2026FY2026 Annual Securities Report (69th term) filedDisclosure
22 Jun 2026Share price reaches a year-to-date high of JPY 4,995Peak AI-materials enthusiasm
Late Jun 2026AGM: all director nominees approved (Sugita 95.78%); Toshihide Tominaga newly electedGovernance
–Daiwa Securities initiates coverage at Outperform, citing price increases resolving the supply/profitability dilemmaBroker support
7 Aug 2026Q1 FY2027: sales JPY 22,819 M (+22.3%), OP JPY 6,172 M (+31.5%), ordinary JPY 6,363 M (2.9% above IFIS consensus), NI JPY 6,688 M (+115.4%, including the subsidy). Full-year guidance unchanged.Strong quarter
7 Aug 2026Corporate presentation: ROIC ≥13% target, PBR 2.5x KPI, Corporate Value Enhancement Committee, new R&D centre (2028)Capital-markets engagement
10 Aug 2026Shares fall 11.9% to JPY 3,355 on heavy volume (2.1 M shares)Market reaction (see note below)
Aug–Sep 2026Shares drift to JPY 2,913 (17 Sep). Consensus ordinary-profit estimate trimmed to about JPY 26.05 bn.De-rating; sector rotation
30 Sep 2026Close JPY 3,220; market cap about JPY 343 bnLatest data point
Late Oct 2026 (scheduled)H1 FY2027 resultsNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from JPY 55,760 Mn in FY2022 to JPY 76,926 Mn in FY2026.
Fuso Chemical Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (JPY Mn)FY2022FY2023FY2024FY2025FY2026
Revenue55,76068,45958,97069,50176,926
Cost of sales32,67940,04838,39743,53147,609
Gross profit23,08128,41120,57325,97129,317

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.